AG 120

Drug Profile

AG 120

Alternative Names: AG-120

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Phase I Glioma; Myelodysplastic syndromes; Solid tumours
  • Phase Unknown Cholangiocarcinoma

Most Recent Events

  • 09 Dec 2016 Agios Pharmaceuticals plans the phase III ClarIDHy trial for Cholangiocarcinoma (Late-stage disease, Inopeable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02989857)
  • 05 Dec 2016 Investigation in Cholangiocarcinoma in USA (PO) before December 2016
  • 05 Dec 2016 Efficacy and adverse events data from a phase I trial in presented at the American Society of Hematology Annual Meeting and Exposition (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top